Articles

Bruce Phelan of Blue Fin discusses Novo Nordisk's purchase of Catalent manufacturing sites to increase its ability to meet the demand for the popular weight loss drug Wegovy.

Implications of Novo Nordisk Acquisition of Catalent Reverberate Through Industry

Examination evaluates investigational stem cell interventions, including how the states have implemented their own policies when it comes to their uses. 

Analyzing State-Based Legislation Surrounding Medical Freedom, Stem Cell Procedures 

The analysis notes that 60% of respondents were setting targets based on AI’s ability to either cut costs or boost productivity.

Survey: Pharma Execs Are Fully Embracing the Use of AI 

Roche and Repare came to terms on a deal in June 2022 to develop and commercialize camonsertib, which included a $125 million upfront payment and could have reached up to $1.2 billion based on clinical, regulatory, commercial, and sales milestones.

Roche Pulls Out of Agreement With Repare Therapeutics to Develop Novel Cancer Therapy

BXCL701 combined with Keytruda (pembrolizumab) is being evaluated for patients with metastatic castration-resistant prostate cancer with small cell neuroendocrine and adenocarcinoma phenotypes.

FDA Fast Tracks Novel Treatment for Metastatic Small Cell Neuroendocrine Prostate Cancer

Cohort study explores value-based insurance designs, while also determining how one’s place of residency can potentially play a role. 

Can Lower Out-of-Pocket Costs Help Improve Diabetes Patients’ Short-Term Health?

In clinical trials, bepirovirsen was found to recognize the RNA used by hepatitis B virus to replicate in infected liver cells.

Bepirovirsen Granted FDA Fast Track Designation for Chronic Hepatitis B 

Eohilia, a corticosteroid developed specifically to treat eosinophilic esophagitis, is comprised of a novel formulation of budesonide taken twice daily for 12 weeks in patients 11 years of age and older.

FDA Approves Eohilia as the First Oral Treatment for Eosinophilic Esophagitis 

According to AbbVie, ImmunoGen's entire oncology portfolio could drive long-term revenue growth, giving the company a potential multi-billion dollar drug that is already on the market.

AbbVie Finalizes Deal to Acquire ImmunoGen With its Pipeline of Antibody Drug Conjugates 

Researchers explore the proportion of approved drugs in the Canadian marketplace that utilize manufacturer-sponsored patient support programs, along with the types of medications that are more likely to do so. 

News